PRIME Institute

09/22/2026

What I tell patients who feel overwhelmed by “heart health” advice:

You don’t need a perfect overhaul.

A SPAN analysis (sleep + physical activity + nutrition tracked together) followed people for about 8 years and counted major heart events — heart attack, stroke, heart failure.

Sticky takeaway: a small combined bump — about 11 more minutes of sleep a day, roughly 5 minutes of moderate activity, and a little better diet quality (think ~¼ cup more vegetables) — was linked with about 10% lower risk of those events.

People with stronger combined SPAN scores had substantially lower risk than those in the lowest group.

Clear caveat: this is observational research (a preprint). “Linked with” is not the same as “guarantees fewer heart attacks.” People who sleep, move, and eat better may differ in other ways too.

Still — these are safe levers I recommend every week.

Comment SLEEP if you’re starting with bedtime tonight — or tell me which lever you’re picking first. Prime Institute | Miami Amy Pearlman Prime Institute | Miami

longevity PRIMEInstitute

09/14/2026

What I tell patients about midlife weight and the heart:

The bathroom scale isn’t the whole story.

A large study of more than 10,000 postmenopausal women followed for about 17 years looked at body fat using DXA scans (a detailed body-composition scan).

Women with the most deep belly fat (visceral fat — the kind that wraps around your organs) had about twice the risk of heart failure compared with women who had the least.

Other fat types mattered too — but deep belly fat was the clearer signal for a common type of heart failure where the heart gets stiff (HFpEF).

Important nuance: this study does NOT mean skip strength training. Building muscle still matters for midlife health.

And association isn’t the same as proof that belly fat alone “causes” heart failure. Blood pressure, diabetes, fitness, and overall health still matter a lot.

Have you ever had a body-composition scan — or only weight and BMI?
Prime Institute | Miami Dr. Michelle Pearlman | Gut & Metabolism Expert
MichellePearlmanMD PRIMEInstituteMiami

09/13/2026

Menopause shifts body composition: more visceral fat, less lean tissue. The 0.8 g/kg/day RDA looks more like a floor than a midlife target.

A 2026 Int J Obes analysis used WHI DXA data (~3,800 women, 50–79) to emulate a 3-year trial of higher protein intake. Benefits showed up around ≥1.2 g/kg/day. At ≥1.5 g/kg vs usual intake: ~13 cm² less visceral fat, ~1% lower body fat, ~2.5 kg lower weight, and a higher lean tissue share.

Caveat that matters: emulated observational design, not a randomized feeding trial. Kidney disease, appetite changes on GLP-1s, and real life all factor in.

Practical take: for many postmenopausal women, moving toward 1.2 g/kg/day — paired with resistance training — is a reasonable starting point. Personalize from there with your clinician. Prime Institute | Miami Dr. Michelle Pearlman | Gut & Metabolism Expert Amy Pearlman

Li et al., Int J Obes. 2026. DOI: 10.1038/s41366-025-01978-0

MidlifeHealth StrengthTraining GLP1 EvidenceBased

09/11/2026

We’re not ready to call GLP-1s a longevity drug — but a new Nature paper is worth reading carefully.

UC Berkeley researchers gave semaglutide to older female mice (about 20 months, roughly analogous to a woman in her 60s). Animals treated for life lived longer: median lifespan rose from 742 to 834 days (~12%, roughly 100 extra days). Muscle and cognitive measures looked better, and several aging hallmarks — including inflammation and senescence-related signals — were quieter.

They also compared the drug to a 24% calorie-restricted diet matched for intake. Semaglutide wasn’t just “eating less”: treated mice did better on memory, exploration, and glucose control, and their metabolic rate stayed closer to baseline while calorie restriction slowed it.

Caveat I always want front and center: this is mice, not humans. It does not prove GLP-1s extend human lifespan. What it does is add a serious biologic hypothesis — that some of the broad clinical benefits we already see (metabolic, cardiovascular, maybe more) may partly track aging pathways, not weight alone.

For patients and clinicians, I keep counseling grounded in what we actually know works: glycemic control, weight, and cardiovascular risk reduction when indicated — while staying curious about the longevity science without overselling it.

Source: Feng Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. Sept 2, 2026. DOI: 10.1038/s41586-026-10940-7 (UC Berkeley / Chen lab; NIH-supported).

What questions are you getting about GLP-1s and “anti-aging” right now?
Dr. Michelle Pearlman | Gut & Metabolism Expert Prime Institute | Miami
PhysicianNutrition EvidenceBasedMedicine MichellePearlmanMD PRIMEInstituteMiami

09/09/2026

If you’re postmenopausal on a GLP-1 and the scale feels “stuck,” hormones may be part of the story — not your willpower.

A 2026 Mayo Clinic retrospective study in The Lancet Obstetrics, Gynaecology, & Women’s Health looked at postmenopausal women on tirzepatide for ≥12 months. Those also on menopause hormone therapy lost about 19% of body weight vs about 14% on tirzepatide alone — and the HRT group showed better cardiometabolic shifts (including triglycerides and related markers).

This is not “HRT is a weight-loss drug.” It’s that estrogen status changes insulin sensitivity, body composition, and how the metabolic system responds — and midlife care should account for that.

What I tell patients: optimize protein and muscle, don’t ignore sleep/stress, and ask whether hormone therapy is appropriate for *you* with a clinician who understands both menopause and obesity medicine. Prospective trials still need to confirm causality — but ignoring the hormone piece in midlife GLP-1 care is outdated.

Curious what you’re seeing in clinic or in your own journey — drop it below.
Prime Institute | Miami Dr. Michelle Pearlman | Gut & Metabolism Expert
Tirzepatide PhysicianPerspective MidlifeHealth ObesityMedicine Nutrition

02/25/2026

Aging isn’t about slowing down… it’s about leveling up.

One of my patients, Karoline, came to me navigating the classic symptoms of the menopause transition — poor sleep, increased stress, low energy, mood fluctuations, and vasomotor symptoms that were disrupting her quality of life.

We took a comprehensive, evidence-based approach:
targeted hormone replacement therapy + strategic nutrition + resistance training + lifestyle optimization.

The result?

Improved sleep
Better mood and stress resilience
Increased energy
Reduced vasomotor symptoms
⬇️ Body fat down 6%
⬆️ Muscle mass up several pounds

This is what happens when you treat the root cause — not just the symptoms.

Muscle is medicine. Hormones matter. Lifestyle is the foundation.

It is absolutely possible to age with power.

If you’re navigating perimenopause or menopause and not feeling like yourself, let’s change that.

Schedule your menopause consultation at Prime Institute to build a personalized, evidence-based plan that works for your body.

.us

05/27/2024

05/24/2024

05/15/2024

02/29/2024

https://wwd.com/beauty-industry-news/wellness/new-weight-loss-drug-vk2735-viking-therapeutics-clinical-trial-1236225098/

Redefining Weight Loss: Innovations in Medication and the Path to True Health

In an era brimming with medical innovations, new weight loss medications are making headlines, offering hope for lasting change. However, it’s crucial to remember these are tools, not magic bullets. Under medical supervision, these medications can be powerful allies, but they’re part of a broader strategy that values safety and holistic health over mere numbers on a scale.

The goal isn’t rapid weight loss but lasting health improvements—optimizing body composition, reducing visceral fat, and preserving muscle mass. This approach ensures we’re not just lighter but healthier, focusing on the long-term journey rather than quick fixes.

Let’s embrace these advancements with caution and wisdom, remembering the importance of professional guidance. For a deeper insight, check out the full discussion in Women’s Wear Daily Together, let’s navigate towards sustainable health, where the real victory lies beyond the scale. Byte MD Amy Pearlman

Findings for a new weight loss drug VK2735 by Viking Therapeutics Inc. were released today, showing it could be more effective than Ozempic.